Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Blood (2025) 146 (Supplement 1): 31.

https://doi.org/10.1182/blood-2025-31

Published: 2025

Journal Articles

Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study

Blood (2025) 146 (Supplement 1): 882.

https://doi.org/10.1182/blood-2025-882

Published: 2025

Journal Articles

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Blood (2025) 146 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2025-1549

Published: 2025

Journal Articles

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 5120.

https://doi.org/10.1182/blood-2025-5120

Published: 2025

Journal Articles

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Blood (2024) 144 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2024-207143

Published: 2024

Journal Articles

Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Blood (2024) 144 (Supplement 1): 779.

https://doi.org/10.1182/blood-2024-207557

Published: 2024

Journal Articles

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Blood (2021) 138 (11): 948–958.

https://doi.org/10.1182/blood.2020010144

Published: 2021

Includes: Supplemental data

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Blood (2018) 132 (Supplement 1): 437.

https://doi.org/10.1182/blood-2018-99-113950

Published: 2018

Journal Articles

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

James M. Foran, MD, Zhuoxin Sun, PhD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, David F. Claxton, MD, Hillard M Lazarus, MD, Daniel A. Arber, MD, Jacob M. Rowe, MD, John Godwin, MD, Yanming Zhang, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Keith W. Pratz, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2018-99-117838

Published: 2018

Journal Articles

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Marlise R. Luskin, Ju-Whei Lee, Hugo F. Fernandez, Omar Abdel-Wahab, John M. Bennett, Rhett P. Ketterling, Hillard M. Lazarus, Ross L. Levine, Mark R. Litzow, Elisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Zhuoxin Sun, Selina M. Luger

Blood (2016) 127 (12): 1551–1558.

https://doi.org/10.1182/blood-2015-07-657403

Published: 2016

Includes: Supplemental data

Journal Articles

Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia

Jinghui Zhang, PhD, Kelly McCastlain, Chunxu Qu, PhD, Gang Wu, PhD, Michael Edmonson, PhD, Yongjin Li, PhD, Lei Wei, PhD, Debbie Payne-Turner, BS, Hiroki Yoshihara, MDPhD, Michelle L. Churchman, PhD, Esmé Waanders, PhD, Panagiotis Ntziachristos, PhD, Iannis Aifantis, PhD, Kathryn G. Roberts, Jing Ma, PhD, Guangchun Song, PhD, John Easton, PhD, Heather L. Mulder, BS, Xiang Chen, PhD, Michael Rusch, BA, Kristy Boggs, PhD, Bhavin Vadodaria, BS, James Dalton, BS, Marcus L Valentine, PhD, Li Ding, PhD, Charles Lu, PhD, Robert S. Fulton, PhD, Lucinda Fulton, PhD, Yashodan Tabib, PhD, Kerri Ochoa, Meenakshi Devidas, PhD, Deqing Pei, Cheng Cheng, PhD, William E. Evans, PharmD, Ching-Hon Pui, MD, Sima Jeha, MD, Richard C. Harvey, PhD, I-Ming L Chen, DVM, MS, Cheryl L. Willman, MD, Guido Marcucci, MD, Clara D. Bloomfield, MD, Jessica Kohlschmidt, PhD BS, MS, Krzysztof Mrozek, MD PhD, Elisabeth Paietta, PhD, Martin S. Tallman, MD, Wendy Stock, MD, Peter M. Voorhees, MD, Janis Racevskis, MD, Jacob M. Rowe, MD, Selina Luger, MD, Steven M. Kornblau, MD, Sheila A Shurtleff, PhD, Susana C. Raimondi, PhD, Elaine R Mardis, PhD, Richard K Wilson, PhD, Stephen P Hunger, MD, Mignon L. Loh, MD, James R. Downing, MD, Charles G. Mullighan

Blood (2015) 126 (23): 693.

https://doi.org/10.1182/blood.V126.23.693.693

Published: 2015

Journal Articles

Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60

Farhad Ravandi, MD, Megan Othus, PhD, Susan O'Brien, MD, Stephen J. Forman, MD, Chul S. Ha, MD, Jeffrey Y. C. Wong, MD, Martin S Tallman, MD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, Geoffrey L. Uy, MD, Uma Borate, MD, Partow Kebriaei, MD, Laura Kingsbury, MRT, Hagop M. Kantarjian, MD, Jerald P. Radich, Harry P. Erba, MD PhD, Frederick R. Appelbaum, MD

Blood (2015) 126 (23): 796.

https://doi.org/10.1182/blood.V126.23.796.796

Published: 2015

Journal Articles

Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL

Blood (2015) 126 (23): 1422.

https://doi.org/10.1182/blood.V126.23.1422.1422

Published: 2015

Journal Articles

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Elisabeth M. Paietta, PhD, Janis Racevskis, PhD, Hugo F Fernandez, MD, Ju-Whei Lee, PhD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Jay P. Patel, Mithat Gönen, PhD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Elihu H. Estey, MD

Blood (2014) 124 (21): 941.

https://doi.org/10.1182/blood.V124.21.941.941

Published: 2014

Journal Articles

Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia

Muhamed Baljevic, MD, Bogdan Dumitriu, MD, Ju-Whei Lee, PhD, Elisabeth Paietta, PhD, Janis Racevskis, Christina Chen, BS, Eytan M. Stein, Robert E Gallagher, MD, Jacob M. Rowe, MD, Frederick R. Appelbaum, MD, Bayard L. Powell, MD, Richard A. Larson, Neal S. Young, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 2375.

https://doi.org/10.1182/blood.V124.21.2375.2375

Published: 2014

Journal Articles

Genetic loss of SH2B3 in acute lymphoblastic leukemia

Arianne Perez-Garcia, Alberto Ambesi-Impiombato, Michael Hadler, Isaura Rigo, Charles A. LeDuc, Kara Kelly, Chaim Jalas, Elisabeth Paietta, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Maddalena Paganin, Giuseppe Basso, Wei Tong, Wendy K. Chung, Adolfo A. Ferrando

Blood (2013) 122 (14): 2425–2432.

https://doi.org/10.1182/blood-2013-05-500850

Published: 2013

Journal Articles

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Mithat Gönen, Zhuoxin Sun, Maria E. Figueroa, Jay P. Patel, Omar Abdel-Wahab, Janis Racevskis, Rhett P. Ketterling, Hugo Fernandez, Jacob M. Rowe, Martin S. Tallman, Ari Melnick, Ross L. Levine, Elisabeth Paietta

Blood (2012) 120 (11): 2297–2306.

https://doi.org/10.1182/blood-2012-02-414425

Published: 2012

Includes: Supplemental data

Journal Articles

Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Blood (2012) 120 (10): 2098–2108.

https://doi.org/10.1182/blood-2012-01-407601

Published: 2012

Includes: Supplemental data

Journal Articles

An activating intragenic deletion in NOTCH1 in human T-ALL

J. Erika Haydu, Kim De Keersmaecker, Mary Kaye Duff, Elisabeth Paietta, Janis Racevskis, Peter H. Wiernik, Jacob M. Rowe, Adolfo Ferrando

Blood (2012) 119 (22): 5211–5214.

https://doi.org/10.1182/blood-2011-10-388504

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia

Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60

Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia

Genetic loss of SH2B3 in acute lymphoblastic leukemia

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

An activating intragenic deletion in NOTCH1 in human T-ALL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only